Xeris Biopharma sues Torrent, Somerset over Recorlev patent infringement

Xeris Biopharma Holdings, Inc.

Filed Hatch-Waxman lawsuit against Torrent Pharmaceuticals and Somerset Therapeutics over ANDA for generic Recorlev.
Lawsuit alleges infringement of four Orange Book patents expiring March 2040 (U.S. Patent Nos. 11,020,393, 11,278,547, 11,903,940, 12,377,096).
Seeks injunction to block generic competition until patent expiry in March 2040.
Recorlev also benefits from Orphan Drug Exclusivity through December 2028.
CEO John P. Shannon cites confidence in IP and intention to vigorously defend.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.